Altimmune shareholders are currently facing unprecedented challenges due to the poor performance of the company's stock, largely attributed to the missteps with the MASH phase 2 trial results and the management's inability to address strategic hurdles. The leadership under Dr. Vipin Garg has been questioned by many for not effectively countering short attacks on the stock, and the noticeable lack of progress in securing valuable partnerships or successful buyout negotiations. Such issues underline the urgent need for a strategic shift in leadership.

Dr. Vipin Garg has undeniably contributed his expertise and diligence to the company, but the current scenario necessitates a transition. By stepping down as CEO and transitioning to the board of directors, Dr. Garg can continue to provide his valuable insights while allowing for new leadership to tackle the prevailing challenges head-on. Raymond Jordt or the CFO, Greg Weaver are very capable replacements with vast experience that can push the company to a quality transaction in a very timely manner with urgency. This change in leadership could foster a renewed sense of confidence among investors and shareholders, potentially revitalizing Altimmune’s market position.

An additional matter of concern is the need for the company to set a firm date for potential partners to submit their bids. This would encourage transparency and convey a clear direction to interested stakeholders. Furthermore, it is imperative that the executives and the board of directors demonstrate their confidence in the company's future by making insider buys. Such actions would not only boost market perception but also serve as a testament to their commitment toward the company's success. 

We call upon Altimmune's shareholder community to advocate for these critical changes. With your support, we can instill trust, drive progress, and lay a foundation for future growth. Sign this petition to ensure your voice is heard and to demand the strategic shift needed at Altimmune.